C91.5
Adult T-cell lymphoma/leukemia (HTLV-1-associated)
Clinical Classification Guidelines
Inclusion Terms
- Acute variant of adult T-cell lymphoma/leukemia (HTLV-1-associated)
- Chronic variant of adult T-cell lymphoma/leukemia (HTLV-1-associated)
- Lymphomatoid variant of adult T-cell lymphoma/leukemia (HTLV-1-associated)
- Smouldering variant of adult T-cell lymphoma/leukemia (HTLV-1-associated)
Medical Intelligence & Overview
Adult T-cell lymphoma/leukemia (ATLL) is a rare cancer of the immune system's T-cells, associated with infection by the human T-cell lymphotropic virus type 1 (HTLV-1). This disease can manifest in several forms, including acute, chronic, lymphomatoid, and smouldering variants. It primarily affects adults and is more common in regions where HTLV-1 is prevalent. The condition is characterized by abnormal growth and proliferation of T-cells, leading to immune system impairment and other health complications.
Causes & Symptoms
Clinical Causes: Infection with HTLV-1: This virus is the primary cause of ATLL. It is a retrovirus that integrates into the T-cells' DNA, triggering malignant transformations. Genetic factors: Some individuals may have genetic predispositions that increase the risk of developing ATLL after HTLV-1 infection. Environmental factors: Certain areas with high HTLV-1 prevalence, such as parts of Japan, the Caribbean, Central Africa, and South America, are associated with increased cases of ATLL.
Key Symptoms: Lymphadenopathy: Swollen or enlarged lymph nodes. Fever and night sweats: Persistent and unexplained fever, often accompanied by drenching night sweats. Weight loss: Significant loss of weight without trying. Fatigue and weakness: Feeling unusually tired or weak. Skin lesions: Rashes, nodules, or skin infiltrations. Gastrointestinal symptoms: Abdominal discomfort, nausea, or changes in bowel habits. Hepatosplenomegaly: Enlarged liver and spleen. Laboratory abnormalities: Elevated white blood cell counts, anemia, or other blood cell irregularities.
Diagnostic & Treatment
Diagnosis Path: Diagnosis of ATLL involves a combination of clinical evaluation, blood tests, and imaging studies. Key diagnostic procedures include: - Blood tests to detect abnormal T-cells and HTLV-1 antibodies. - Lymph node or tissue biopsies to examine the cellular structure and identify malignant T-cells. - Imaging techniques like CT scans or PET scans to assess the extent of disease spread. - Molecular testing for genetic mutations or viral markers associated with ATLL.
Treatment Protocols: Treatment options for ATLL depend on the variant and severity of the disease. Typically, they include: - Chemotherapy to target and destroy malignant cells. - Antiviral therapies aimed at controlling HTLV-1 infection. - Immunotherapy, such as monoclonal antibodies, to boost the immune response. - Stem cell or bone marrow transplants in selected cases. - Supportive care to manage symptoms, infections, and improve quality of life. Due to its aggressive nature, ATLL often requires comprehensive treatment plans developed by specialized healthcare teams.
Clinical Advice & FAQs
Billing Guidance
Is C91.5 a billable ICD-10 code?
Yes, C91.5 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report C91.5?
Clinical documentation must specify the nature of Adult T-cell lymphoma/leukemia (HTLV-1-associated) and any associated comorbidities for accurate reporting.
Cite this Clinical Reference